within Pharmacolibrary.Drugs.G_GenitoUrinarySystemAndSexHormones.G01A_AntiinfectivesAndAntisepticsExclCombinationsWithCorticosteroids.G01AX17_Dapivirine;

model Dapivirine
  extends Pharmacolibrary.Drugs.ATC.G.G01AX17;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>G01AX17</td></tr><td>route:</td><td>vaginal</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Dapivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used primarily in the form of a vaginal ring to prevent HIV-1 infection in women. The drug is designed for topical use to achieve high local concentrations and minimal systemic exposure. Dapivirine vaginal rings have received a positive scientific opinion from the European Medicines Agency and are recommended by the World Health Organization for HIV prevention in women.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult women, post-menopausal and reproductive age, enrolled in clinical trials assessing dapivirine vaginal ring (25 mg), steady-state achieved after repeated monthly administration.</p><h4>References</h4><ol><li><p>das Neves, J, et al., &amp; Sarmento, B (2014). Biodistribution and pharmacokinetics of dapivirine-loaded nanoparticles after vaginal delivery in mice. <i>Pharmaceutical research</i> 31(7) 1834–1845. DOI:<a href=\"https://doi.org/10.1007/s11095-013-1287-x\">10.1007/s11095-013-1287-x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/24449442/\">https://pubmed.ncbi.nlm.nih.gov/24449442</a></p></li><li><p>Robinson, JA, et al., &amp; Hendrix, CW (2017). Comparison of Dapivirine Vaginal Gel and Film Formulation Pharmacokinetics and Pharmacodynamics (FAME 02B). <i>AIDS research and human retroviruses</i> 33(4) 339–346. DOI:<a href=\"https://doi.org/10.1089/AID.2016.0040\">10.1089/AID.2016.0040</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27809557/\">https://pubmed.ncbi.nlm.nih.gov/27809557</a></p></li><li><p>Achilles, SL, et al., &amp; Chen, BA (2024). Phase 1 randomized trials to assess safety, pharmacokinetics, and vaginal bleeding associated with use of extended duration dapivirine and levonorgestrel vaginal rings. <i>PloS one</i> 19(6) e0304552–None. DOI:<a href=\"https://doi.org/10.1371/journal.pone.0304552\">10.1371/journal.pone.0304552</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38838028/\">https://pubmed.ncbi.nlm.nih.gov/38838028</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Dapivirine;
